

UROLOGIC ONCOLOGY

Seminars and Original Investigations

Table of Contents: Volume 37, Number 9, September 2019

News and Topics

- 565** **Cystectomy readmissions and the opioid epidemic: An opportunity for synergistic improvement**
Tudor Borza, Caprice C. Greenberg, Bruce L. Jacobs, Brent K. Hollenbeck, David F. Jarrard and Ted A. Skolarus, for the CLEAR Working Group

Letters to the Editor

- 570** **Risk assessment of bladder cancer: lifestyle and nutritional contribution**
Tomoyuki Kawada
- 571** **Replay by authors: Serum testosterone level is a useful biomarker for determining the optimal treatment for castration-resistant prostate cancer**
Juan Morote and Imma Comas

Clinical - Bladder

- 572.e1** **Predictive value of phenotypic signatures of bladder cancer response to cisplatin-based neoadjuvant chemotherapy**
Patrick J. Hensley, Natasha Kyprianou, Matthew S. Purdom, Daheng He, Vincent DiCarlo, Chi Wang and Andrew C. James
- 572.e13** **Factors influencing ICU admission and associated outcome in patients undergoing radical cystectomy with enhanced recovery pathway**
Kai W. Cheng, Ankeet Shah, Soroush Bazargani, Gus Miranda, Jie Cai, Monish Aron, Anne Schuckman, Mihir Desai, Inderbir Gill, Siamak Daneshmand and Hooman Djaladat
- 572.e21** **The impact of pathologic response to neoadjuvant chemotherapy on conditional survival among patients with muscle-invasive bladder cancer**
Nikhil Waingankar, Rachel Jia, Kathryn E. Marqueen, Francois Audenet, John P. Sfakianos, Reza Mehrazin, Bart S. Ferket, Madhu Mazumdar and Matthew D. Galsky
- 573.e1** **Low awareness, adherence, and practice but positive attitudes regarding lifestyle recommendations among non-muscle-invasive bladder cancer patients**
Ellen Westhoff, Ellen Kampman, Katja K. Aben, Inge G. Hendriks, Johannes Alfred Witjes, Lambertus A. Kiemeny and Alina Vrieling
- 573.e9** **Impact of RAGE polymorphisms on urothelial cell carcinoma clinicopathologic characteristics and long-term survival**
Sheng-Chun Hung, Shian-Shiang Wang, Jian-Ri Li, Chuan-Shu Chen, Chia-Yen Lin, Li-Wen Chang, Kun-Yuan Chiu, Chen-Li Cheng, Yen-Chuan Ou and Shun-Fa Yang

Laboratory - Bladder

- 573.e19** **Morphologic and genomic characterization of urothelial to sarcomatoid transition in muscle-invasive bladder cancer**
Vera Genitsch, Attila Kollár, Gillian Vandekerkhove, Jennifer Blarer, Marc Furrer, Matti Annala, Cameron Herberts, Armin Pycha, Joep J. de Jong, Yang Liu, Friedemann Krentel, Elai Davicioni, Ewan A. Gibb, Marianna Kruihof-de Julio, Alexander W. Wyatt and Roland Seiler

(contents continued on next page)

Table of Contents (*continued*)

Clinical - Prostate

- 574.e1** **The estimated prevalence of missed positive lymph nodes based on extent of lymphadenectomy at radical prostatectomy**
Nicholas H. Chakiryan, Ann Martinez Acevedo, Michael J. Conlin, Mark Garzotto, Yiyi Chen, Jen-Jane Liu, Christopher L. Amling and Ryan P. Kopp
- 574.e11** **Comparative effectiveness of treatments for high-risk prostate cancer patients**
Ravishankar Jayadevappa, David I. Lee, Sumedha Chhatre, Thomas J. Guzzo and Stanley B. Malkowicz
- 574.e19** **⁶⁸Ga-PSMA PET/CT: Does it predict adverse pathology findings at radical prostatectomy?**
Snir Dekalo, Jonathan Kuten, Nicola J Mabjeesh, Avi Beri, Einat Even-Sapir and Ofer Yossepowitch
- 575.e1** **Prostate cancer prognosis in men with other malignancies prior to radical prostatectomy**
Peter Klippenstein, Thorsten Schlomm, Gunhild von Amsberg, Burkhard Beyer, Raisa S. Pompe, Uwe Michl, Georg Salomon, Imke Thederan, Lars Budäus, Hans Heinzer, Derya Tilki, Alexander Haese, Hartwig Huland, Markus Graefen, Thomas Steuber and Pierre Tennstedt
- 575.e9** **The current landscape of low-value care in men diagnosed with prostate cancer: what is the role of individual hospitals?**
Marieke J. Krimphove, Alexander P. Cole, David F. Friedlander, David-Dan Nguyen, Stuart R. Lipsitz, Paul L. Nguyen, Kerry L. Kilbridge, Adam S. Kibel, Luis A. Kluth and Quoc-Dien Trinh
- 575.e19** **The prognostic value of zonal origin and extraprostatic extension of prostate cancer for biochemical recurrence after radical prostatectomy**
Kimiharu Takamatsu, Kazuhiro Matsumoto, Kazunori Shojo, Nobuyuki Tanaka, Toshikazu Takeda, Shinya Morita, Takeo Kosaka, Ryuichi Mizuno, Toshiaki Shinojima, Eiji Kikuchi, Hiroshi Asanuma and Mototsugu Oya

Laboratory - Prostate

- 576.e1** **TRIM24 as an independent prognostic biomarker for prostate cancer**
Anne Offermann, Doris Roth, Marie Christine Hupe, Silke Hohensteiner, Finn Becker, Vincent Joerg, Jessica Carlsson, Christiane Kuempers, Julika Ribbat-Idel, Lars Tharun, Verena Sailer, Jutta Kirfel, Maria Svensson, Ove Andren, Verena Lubczyk, Rainer Kuefer, Axel S. Merseburger and Sven Perner

Clinical - Kidney

- 576.e11** **Diabetes and kidney cancer survival in patients undergoing nephrectomy: A Canadian multi-center, propensity score analysis**
Madhur Nayan, Shreya Jalali, Anil Kapoor, Antonio Finelli, Alan So, Ricardo Rendon, Rodney H. Breau, Luke T. Lavalley, Simon Tanguay, Daniel Heng, Jun Kawakami, Naveen S. Basappa, Georg Bjarnason, Frederic Pouliot and Robert J. Hamilton
- 576.e17** **Trends and outcomes in contemporary management renal cell carcinoma and vena cava thrombus**
Alp Tuna Beksac, Qainat N. Shah, David J. Paulucci, Jing Zhi Lo, Kennedy E. Okhawere, Amr A. Elbakry, Bheesham D. Dayal, Reza Mehrazin, Daniel Eun, Ashok Hemal, Ronney Abaza, John P. Sfakianos and Ketan K. Badani
- 577.e1** **A preoperative nomogram to predict major complications after robot assisted partial nephrectomy (UroCCR-57 study)**
Zine-Eddine Khene, Benoit Peyronnet, Jean-Christophe Bernhard, Neil J. Kocher, Christophe Vaessen, Nicolas Doumerc, Benjamin Pradere, Thomas Seisen, Jean-Baptiste Beauval, Grégory Verhoest, Mathieu Roumiguié, Alexandre De la Taille, Franck Bruyere, Morgan Roupert, Arnaud Mejean, Romain Mathieu, Shahrokh Shariat, Jay D. Raman and Karim Bensalah, the members of the French Committee of Urologic Oncology (CCAFU)
- 577.e9** **Cytoreductive nephrectomy in patients with metastatic renal cell carcinoma and venous thrombus—Trends and effect on overall survival**
Andrew T. Lenis, Claire S. Burton, Vishnukamal Golla, Aydin Pooli, Izak Faiena, David C. Johnson, Amirali Salmasi, Alexandra Drakaki, Kiran Gollapudi, Jeremy Blumberg, Allan J. Pantuck and Karim Chamie
- 577.e17** **Accuracy of clinical nodal staging and factors associated with receipt of lymph node dissection at the time of surgery for nonmetastatic renal cell carcinoma**
Kushan D. Radadia, Zorimar Rivera-Núñez, Sinae Kim, Nicholas J. Farber, Joshua Sterling, Marissa Falkiewicz, Parth K. Modi, Sharad Goyal, Rahul Parikh, Robert E. Weiss, Isaac Y. Kim, Sammy E. Elsamra, Thomas L. Jang and Eric A. Singer

Table of Contents (*continued*)

Laboratory - Kidney

- 578.e1** **The role of p53 isoforms' expression and p53 mutation status in renal cell cancer prognosis**
Marijana Knezović Florijan, Petar Ozretić, Maro Bujak, Laura Pezzè, Yari Ciribilli, Željko Kaštelan, Neda Slade and Tvrtko Hudolin

Clinical - Testis

- 578.e11** **Adherence to guideline recommendations for lymph node dissection in squamous cell carcinoma of the penis: Effect on survival and complication rates**
Francesco A. Mistretta, Elio Mazzone, Carlotta Palumbo, Sophie Knipper, Zhe Tian, Sebastiano Nazzani, Derya Tilki, Gennaro Musi, Paul Perrotte, Emanuele Montanari, Shahrokh F. Shariat, Fred Saad, Alberto Briganti, Ottavio de Cobelli and Pierre I. Karakiewicz

Seminar Articles

- 579** **Radiation therapy for prostate cancer: An evolving treatment modality**
Ronald C. Chen
- 582** **A review of salvage treatment options for disease progression after radiation therapy for localized prostate cancer**
Ethan M. Steele and Jordan A. Holmes
- 599** **The current state of randomized clinical trial evidence for prostate brachytherapy**
Robert T. Dess, Payal D. Soni, William C. Jackson, Alejandro Berlin, Brett W. Cox, Shruti Jolly, Jason A. Efstathiou, Felix Y. Feng, Amar U. Kishan, Bradley J. Stish, Thomas M. Pisansky and Daniel E. Spratt
- 611** **Role of novel imaging in the management of prostate cancer**
Karen M. Xu, Ronald C. Chen, David M. Schuster and Ashesh B. Jani
- 619** **Moderate hypofractionation and stereotactic body radiation therapy in the treatment of prostate cancer**
Jason M. Beckta, Jason D. Nosrati and James B. Yu
- 628** **Proton therapy for prostate cancer: A review of the rationale, evidence, and current state**
Trevor J. Royce and Jason A. Efstathiou